AstraZeneca PLC (AZN) operating KPIs

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30

$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca other Rare Disease medicines — Worldwide product sales ($M) ($M)

Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables

Quarterly Annual

Latest, Q2 2026

Period ended Jun 30, 2026

Change on a year earlier

+34.5%

55 in Q2 2025

History

6 quarters

Since Q1 2025

Sources

Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Other Rare Disease medicines — Worldwide product sales ($M) ($M)	Year on year	Source
Q2 2026	Jun 30, 2026	74	+34.5%	Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026	Mar 31, 2026	74	+27.6%	Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025	Dec 31, 2025	55	–	Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025	Sep 30, 2025	64	–	Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025	Jun 30, 2025	55	–	Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025	Mar 31, 2025	58	–	Form 6-K FY2025Q1 Earnings Release ↗

Breakdown

What makes up other rare disease medicines — worldwide product sales ($m)

Cite this data

StockData. (2026). AstraZeneca Other Rare Disease medicines — Worldwide product sales ($M) ($M), quarterly Q1 2025–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_other_rare_world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.